NCT07816328
Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below.
- Minor Trial sites expanded: 1 → 5 locations
- Primary and study completion dates: Jun 2, 2028 to May 24, 2028
- Notable Recruitment opened
- Primary and study completion moved earlier from Jul 17, 2028 to Jun 2, 2028
- Start date changed from estimate of Nov 9, 2026 to Sep 21, 2026
- Study sites: 0 to 1
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Proportion of participants achieving Urticaria Activity Score over 7 days (UAS7) ≤6 (yes/no)
Timeframe: Week 24
Secondary (7)
Proportion of participants achieving UAS7 ≤6 (yes/no)
Proportion of participants achieving UAS7 =0 (yes/no)
Proportion of participants achieving Angioedema Activity Score over 7 days (AAS7) =0.
Proportion of participants achieving of Dermatology Life Quality Index (DLQI) =0/1
Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Show 2 moreShow less
Proportion of participants achieving UAS7 ≤6 under the treatment algorithm compared with historical omalizumab (300 mg every 4 weeks) data.
Proportion of participants achieving UAS7 =0 under the treatment algorithm compared with historical omalizumab (300 mg every 4 weeks) data.
Arms and interventions
RemibrutinibExperimental
Participants will receive remibrutinib 25 mg twice a day for 12 weeks.
Remibrutinib or OmalizumabExperimental
Participants will receive remibrutinib 25 mg twice a day. At Week 12, well-controlled participants (UCT7 ≥12) continue remibrutinib, while participants with inadequate control (UCT7 \<12) escalate to omalizumab 300 mg every 4 weeks.
Drugs: Remibrutinib, Omalizumab
Sites
5 sites in 3 countries
Japan 3, Hong Kong 1, South Korea 1